Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10593186 | Bioorganic & Medicinal Chemistry Letters | 2012 | 4 Pages |
Abstract
PI3K is a promising therapeutic target for cancer. With PI-103 as the lead compound, we designed and synthesized 4-(2-arylpyrido[3â²,2â²:3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl)morpholine derivatives. 9, 10a, 10d, 10e had the IC50 against PI3Kα comparable with PI-103. All of the compounds showed selectivity over 15 tested protein kinases and anti-proliferative activity at micromolar concentration against several cancer cell lines.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jia Wang, Xiang Wang, Yanhong Chen, Simeng Chen, Guang Chen, Linjiang Tong, Linghua Meng, Yuyuan Xie, Jian Ding, Chunhao Yang,